Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas

NCT04083235 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT04083235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04083235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
February 11, 2020
Completion date
February 18, 2025
Enrollment
770 (actual)
Sites
200

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic adenocarcinoma of the pancreas